Discover perspectives of our leaders on the COVID-19 pandemic by exploring this growing collection of articles, videos and more.
Novartis CEO joins Sal Khan in the Khan Academy Homeroom
In this podcast, Novartis CEO Vas Narasimhan and Sal Khan discuss about modern day breakthroughs in the world of medicine and what we can expect for the future of health as we emerge from COVID-19.
Novartis CEO outlines how to improve pandemic preparedness, warns another one is bound to happen
Novartis CEO Vas Narasimhan discusses how to improve pandemic preparedness at the CNBC Evolve Global Summit.
Can partnerships help boost vaccine supply?
Interview with Dr Steffen Lang, Global Head of Novartis Technical Operations on how Novartis is involved in manufacturing COVID-19 vaccines.
Monocle’s The Big Interview Podcast
Monocle’s editorial director, Tyler Brûlé, is joined by Vas Narasimhan, CEO of Novartis.
Listen to podcast
CEO of Sandoz, Richard Saynor, reflects on the past year and on-going efforts to maintain overall manufacturing and supply security for essential medicines.
Pierre Bourdage, Global Head of Biopharmaceuticals at Sandoz, provides insight into the state and future of the biosimilars market and discusses how to adapt to ‘the new normal’.
On Bloomberg Live, Novartis CEO Vas Narasimhan shares insights on the importance of collaboration during COVID-19.
A mini-video-series in which Novartis leaders connect on video calls to discuss some of the biggest questions for healthcare as we navigate the global pandemic.
Novartis Chief Digital Officer Bertrand Bodson talked to FiercePharma about pharma’s COVID-19 pandemic reputation boost with potential tech hires.
Developing drugs during a pandemic
Novartis CEO Vas Narasimhan spoke with WIRED’s Steven Levy and shared his perspective on some of the ways forward for the industry and the world.
Helping clinical trial patients during a lockdown
Yan Zhao talks about how her team in China responded to an emerging public health crisis.
Cancer didn’t stop for COVID-19
Myriam Mendila describes how Novartis continued supporting cancer patients and healthcare professionals during the pandemic.
Moving towards the next normal
How changes driven by COVID-19 may shape pharma manufacturing in the long term.
Overcoming manufacturing challenges
Novartis Technical Operations adapts to meet drug donation plans and ensure business continuity.
Supply chain organization during the COVID-19 pandemic
Balancing priorities of combating the crisis and ongoing trials.
Proactive scenario planning and supply risk management
Steffen Lang on communication, data and automation during the crisis.
Enabling a stable supply of medicines during COVID-19
What are the key factors ensuring Novartis supply chains remain operational during the pandemic?
Novartis CEO Vas Narasimhan talks with Fortune editor-in-chief Clifton Leaf about health care's present and future.
Listen to podcast
Streamlining systems to respond to COVID-19
Paul Aliu and his team quickly address requests for Novartis medicines during the pandemic.
Joining Monocle’s The Big Interview Podcast
Vas Narasimhan in Monocle's radio show, The Big Interview.
NYSE called Novartis CEO Vas Narasimhan to learn how Novartis is applying what they learned from fighting H1N1 to the current COVID-19 pandemic.
Watch on IGTV
It takes an R&D village to fight a pandemic
Mr. Tougas works in a Novartis task force devoted to fight the virus.
President of Novartis Oncology Susanne Schaffert speaks with oncology experts to share insights and offer hope on navigating the COVID-19 pandemic.
Watch Video Series
In light of COVID-19, Ann Aerts, Head of the Novartis Foundation, shares her point of view on Morning Consult.
Novartis CEO Vas Narasimhan spoke to Milken Institute Chairman, Michael Milken about COVID-19 during their 21st episode of the Milken Institute Podcast Series.
Download the transcript (PDF 1.1 MB)
Coronavirus (COVID-19) Q&A
Novartis CEO Vas Narasimhan answers questions about COVID-19.
Choosing optimism in the face of crisis
LinkedIn article written by Vas Narasimhan, CEO of Novartis.
This site is intended for a global audience.